Denali Therapeutics Inc. ($DNLI)
Filing Information
| Accession Number | 0001193125-26-259680 |
|---|---|
| Form Type | 4 |
| Filing Date | Jun 5, 2026 |
| Document | View SEC Filing |
Transactions
4
Total Shares
51,268
Total Value
$0.00
P&L
+inf% (+$1,000,751.36)
Transactions
| Name | Title | Security | Derivative | Transaction Date | Type | Shares | Price | Total Cost | Shares After | Direct/Indirect | Nature of Ownership | Actions |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Director | Common Stock | โ | Jun 3, 2026 | Grant/Award | 6,408 | $0.00 | $0.00 | 343,275 | Indirect | See Footnotes | View Details | |
Director | Common Stock | โ | Jun 3, 2026 | Grant/Award | 6,408 | $0.00 | $0.00 | 3,422,366 | Indirect | See Footnotes | View Details | |
Director | Non-Qualified Stock Option (right to buy) | Derivative | Jun 3, 2026 | Grant/Award | 19,226 | $0.00 | $0.00 | 19,226 | Indirect | See Footnotes | View Details | |
Director | Non- Qualified Stock Option (right to buy) | Derivative | Jun 3, 2026 | Grant/Award | 19,226 | $0.00 | $0.00 | 19,226 | Indirect | See Footnotes | View Details |